<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Studies on the neuroprotective effect of <z:chebi fb="131" ids="25107">magnesium</z:chebi> treatment in animal models of focal and global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> have produced inconsistent results </plain></SENT>
<SENT sid="1" pm="."><plain>Nevertheless, two <z:chebi fb="131" ids="25107">magnesium</z:chebi> <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> phase III trials (IMAGES and FAST-MAG) have either been completed or are planned </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we decided to re-evaluate the efficacy of <z:chebi fb="131" ids="25107">magnesium</z:chebi> following focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Two experiments were carried out in two independent laboratories based in Australia </plain></SENT>
<SENT sid="4" pm="."><plain>Both used the intraluminal thread method to induce focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the rat </plain></SENT>
<SENT sid="5" pm="."><plain>In the Perth study the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) was occluded for 45 min and body temperature was controlled during and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In the Canberra laboratory the <z:chebi fb="70" ids="34342">MCA</z:chebi> was occluded for 2 h and body temperature was only controlled during surgery </plain></SENT>
<SENT sid="7" pm="."><plain>Three different doses (180, 360, or 720 micromol/kg) of <z:chebi fb="0" ids="32599">MgSO4</z:chebi> in the Perth study and two different <z:chebi fb="0" ids="32599">MgSO4</z:chebi> doses (370 or 740 micromol/kg) in the Canberra study were intravenously or intra-arterially administered immediately before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Control animals were given an equal volume of <z:mpath ids='MPATH_458'>normal</z:mpath> saline just before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in both studies </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-four or 72 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was determined following 2',3',5'-triphenyl-2H-tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining </plain></SENT>
<SENT sid="10" pm="."><plain>No significant differences (P &gt; 0.05) in total, cortical and striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes between saline and <z:chebi fb="0" ids="32599">MgSO4</z:chebi> treated animals were observed in either study </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude <z:chebi fb="0" ids="32599">MgSO4</z:chebi> does not reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when administered before focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
</text></document>